Introduction
Cancer of the cervix uteri is the second most frequent cancer in women worldwide, with an estimated 493 000 incident cases and 273 000 deaths per year. Approximately 83% of cases occur in less-developed countries, where cervical cancer is the leading cause of cancer death in women (Ferlay et al., 2005 ).
An estimated 39.5 million people worldwide were living with HIV at the end of 2006, of whom two-thirds reside in sub-Saharan Africa (Joint United Nations Programme on HIV/AIDS and World Health Organization, 2006) . HIV, human papillomavirus (HPV), and cervical cancer are epidemiologically associated with one another. Opportunistic infections and cancers such as cervical cancer are symptoms of AIDS, owing to a reduction in the number of CD4 T-helper lymphocytes and impairment in T-cell functions caused by HIV. Invasive cervical carcinoma (ICC) was classified as an AIDS-defining illness in 1993 by the United States Centers for Disease Control and Prevention after evidence became available of a higher prevalence of cervical squamous intraepithelial lesions (SIL) in HIV-positive immunosuppressed women (Centers for Disease Control, 1992) .
The introduction of highly active antiretroviral therapy (HAART) has improved significantly the morbidity and mortality of patients with HIV infection, owing largely to immune reconstitution of the host. For a long time, antiretroviral therapy was out of reach for people in developing countries. However, more recently, treatment programmes have been put in place and by the end of 2006, an estimated 28% of people living with HIV and needing treatment in those countries had access to antiretroviral therapy (World Health Organization, 2007) .
The aim of this work is to review the current knowledge on HIV, HPV, and cervical neoplasia/cancer and the effect of HAART on HPV natural history, cervical dysplasia, and cancer in women with HIV infection (WHIV).
Methods
MEDLINE was searched using the terms 'human papillomavirus', 'HPV', 'HIV', 'cervix', 'neoplasm', and 'antiretroviral' to retrieve articles published before December 2006. Additional reports were also obtained by reviewing the reference sections of obtained articles.
Results

Association between HIV and human papillomavirus infection
HPV infection is the central cause of cervical cancer (Bosch et al., 1995) and certain high-risk (HR) types (i.e. HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66)
Most cross-sectional studies show that the prevalence of cervical HPV DNA is higher in HIV-positive than in HIV-negative women, even after controlling for potential confounding factors such as age and sexual behavior (Sun et al., 1995; Temmerman et al., 1999; Strickler et al., 2005) . Table 1 shows that the ratios of HPV prevalence between HIV-positive and HIV-negative women were consistently greater than 1 in the United States, ranging from 1.4 in high-risk adolescents to 2.7 in high-risk women in Maryland. Respective HPV prevalence ratios in other American countries ranged from 1.5 in Brazil to 3.2 in Honduras; in Europe from 1.1 in Austria to 9.3 in Italy; and in Africa from 1.0 in Tanzania to 3.6 in Senegal. Given that both HIV and HPV are sexually transmitted and thus share some risk factors, these positive associations found in the majority of available cross-sectional data were not unexpected.
Cohort studies provided the most persuasive evidence that the risk of acquiring new (incident) cervical HPV infections may be higher in HIV-positive than in HIVnegative women (Sun et al., 1997; Minkoff et al., 1998; Silverberg et al., 2002; Chaturvedi et al., 2005; Strickler et al., 2005) . The majority of these studies, however, did not adequately control for differences in sexual behavior between WHIV and HIV-negative women to determine whether these two infections are simply transmitted sexually at the same time, or whether WHIV are truly at a higher risk of HPV acquisition.
Impact of HIV on human papillomavirus persistence
Persistent HPV infection significantly increases the risk of progression to cervical dysplasia (Remmink et al., 1995; Walboomers et al., 1999; Kjaer et al., 2002) . Although data are limited, it has been demonstrated that WHIV have a higher risk of developing persistent HPV infections than HIV-negative women. This has been shown for persistence of any HPV type (persistence of 24% in HIVpositive vs. 4% in HIV-negative women, Ahdieh et al., 2000; and 61 vs. 23%, Sun et al., 1997, respectively) , as well as for persistence of HPV types 16 or 18 (13 vs. 2%, Ellerbrock et al., 2000, respectively) , and for persistence of any HR HPV types (Minkoff et al., 1998) .
Impact of HIV on the range of human papillomavirus types
Several studies have found a broader range of both high-risk and low-risk HPV types in HIV-positive compared with HIV-negative women (Gonçalves et al., 1999; Palefsky et al., 1999; Ellerbrock et al., 2000) . Others, however, have reported no difference (Jamieson et al., 2002) . Types that were identified more frequently include HPV35, 44, 54, 59, 66 (Cappiello et al., 1997) and HPV11, 39, 43, 51, and 59 in Zimbabwe (Baay et al., 2004) . Broker et al. (2001) compared HIV-positive with HIV-negative women who were immunosuppressed as a result of renal failure. In the group of WHIV, a higher prevalence of nononcogenic types from the 'novel' A3 phylogenetic subgroup (HPV61, 62, 72, 81, 83, and 84) was found.
In a recent meta-analysis of 20 studies including 5578 WHIV worldwide (Clifford et al., 2006) , the most striking finding was that WHIV with high-grade SIL (HSIL) had an increased risk of prevalent multiple type HPV infections [odds ratio (OR): 9.3, 95% confidence interval (CI): 6.9-12] compared with women with HSIL from the general population. Whether multiple type infections pose a higher risk for cervical intraepithelial neoplasia (CIN) or ICC than single-type infections is still under debate (Ho et al., 1998; Levi et al., 2002; Cuschieri et al., 2004; Herrero et al., 2005; Trottier et al., 2006) . Furthermore, HPV16 was less frequently associated with HSIL in WHIV, compared with women from the general population (Clifford et al., 2006) . These results were consistent with previous reports among women with normal and abnormal cytology in the Women's Interagency HIV Study (WIHS) and HIV Epidemiology Research Study cohorts from the United States (Strickler et al., 2003) . The HIV Epidemiology Research Study also showed that HPV16 was more weakly associated with immune status than the other HPV types, suggesting that HPV16 may be better at avoiding the effects of immune surveillance, even among immunocompetent women.
One study from Kenya compared HPV type distribution in ICC among 51 WHIV with ICC and 153 HIV-negative women with ICC and found that HIV-positivity was associated mainly with a higher prevalence of multiple HPV type infections, but the distribution of HPV types was similar in the two groups (De Vuyst et al., 2008) .
To draw conclusions from these HPV typing data, comparable PCR primer sets need to be used to enable identification of the same range of HPV types. Further systematic work is needed to compare the distribution of HPV types in women infected with HIV type-1 and HIV type-2.
Impact of HIV on human papillomavirus viral load
Although relatively few data are available on the effect of HIV infection on HPV viral load, most studies show a positive association (Serwadda et al., 1999; Jamieson et al., 2002) . HPV viral load was increased in HIV-positive compared with HIV-negative women, among women with normal cytology (Womack et al., 2000) , HSIL (Weissenborn et al., 2003) and among women with HSIL and HPV16 infection (Lefevre et al., 2004) .
Further data are needed to determine whether HPV viral loads are consistently higher in WHIV, and whether this might explain the higher risk of SIL in these women (Delmas et al., 2000; Duerr et al., 2001; Lillo et al., 2005) .
Role of HIV-related immunosuppression in human papillomavirus infection
Among WHIV, several studies have consistently shown a higher prevalence of any HPV DNA Jamieson et al., 2002; Strickler et al., 2005) , or high-risk HPV types (16, 18, 31, 33, 35 and 45) specifically, as well as more persistent HPV infections (Sun et al., 1997; Ahdieh et al., 2000; Lillo et al., 2001) , in women with CD4 counts lower than 200 cells/mm 3 . Plasma HIV RNA level and CD4 counts in combination seem to have a stronger association with HPV incidence than with HPV persistence (Strickler et al., 2005) . In a modeling study, Goldie et al. (2001) estimated the prevalence of transient and A study by Broker et al. (2001) concluded that HPV infections are very common and are normally held in a subclinical (latent) state by a functional immune system and that these infections can be reactivated under immunosuppressive conditions, a finding also suggested by Strickler et al. (2005) .
Other possible mechanisms
Although there is no great support from available data, HIV could impact on HPV natural history through mechanisms besides the increased immune-escape pathway in immunosuppressed women. HIV may have a direct viral-viral interaction with HPV, given that both viruses infect macrophages (Clarke and Chetty, 2002) . In-vitro studies have indicated that expression of the HIV tat protein may increase the expression of HPV E1 and L1 viral genes (Dolei et al., 1999) and HPV16 E7 transcription (Vernon et al., 1993) . It is uncertain, however, whether HIV may increase the risk of HPV replication or transcription in vivo. Alternatively, inflammatory responses induced by HIV may interfere with a woman's ability to mount an effective immune response to HPV infection, leading to the development of more persistent HPV infections.
Association between HIV and cervical dysplasia
Two terminologies are used to determine stages of cervical neoplasia. Cytological results are reported using the Bethesda nomenclature: HSIL and low-grade SIL (LSIL; Kurman and Solomon, 1994) ; histological results are reported by the International Federation of Gynecology and Obstetrics CIN1-2-3 classification system.
Prevalence and incidence of intraepithelial lesions in HIV-positive women SIL prevalence has been shown to be consistently higher in HIV-positive compared with HIV-negative women. Wright et al. (1994) reported CIN prevalence of 20.0 and 4.2% in HIV-positive and HIV-negative women, respectively. Other studies have found CIN prevalence rates in the order of 26.5 and 7.5% (Six et al., 1998) and 17.2 and 3.5% , respectively. Table 2 shows a summary of results from studies comparing the prevalence of LSIL and HSIL in WHIV and HIV-negative women. Studies in WHIV report the prevalence of LSIL and HSIL as 28.6 and 14%, respectively, in the United Kingdom (Olaitan et al., 1997) , 15.4 and 7.9% in the United States , and 21.0 and 2.8% in a European cohort (Delmas et al., 2000) . Associations of similar magnitudes have been found in African settings.
Cohort studies consistently show an increased incidence rate of SIL in HIV-positive compared with HIV-negative women (Table 3) . To our knowledge, few cohort data in WHIV from Africa are available. A study from the Ivory Coast described the evolution of 94 LSIL over a median follow-up time of 5 months. A 4.3-fold higher rate of LSIL persistence in HIV-positive compared with HIVnegative women (76 vs. 17.9%; La Ruche et al., 1999) was present. A cohort study in Senegal found an increased risk of development of HSIL in women with HIV-1 and, to a lesser degree, HIV-2. After adjustment for high-risk HPV types and persistence, however, infection with HIV was no longer a risk factor for development of HSIL (Hawes et al., 2006) .
Progression and regression of precancerous lesions in women with HIV infection
Studies have consistently shown increased progression rates of LSIL to HSIL in HIV-positive compared with HIV-negative women. Six et al. (1998) reported progression among 38.1% of WHIV with LSIL, whereas none of the HIV-negative women progressed over a 1-year followup period. Massad et al. (2001) showed greater LSIL progression rates within 6 months after diagnosis among HIV-positive compared with HIV-negative women (13.6 vs. 6.8%) and reduced regression rates (43.3 vs. 66.2%), respectively. In contrast, Robinson et al. (2002) found no differences in progression or regression of LSIL for WHIV, the majority of whom were on antiretroviral therapy.
Role of immunosuppression in intraepithelial lesions
The correlation between HIV-associated immunosuppression and a higher prevalence of SIL has been described as early as 1991 in a group of HIV-infected and allograft recipients (Vermund et al., 1991) . Subsequently, the incidence of SIL has also been shown to be higher in women with lower CD4 counts (Delmas et al., 2000; Massad et al., 2001; Schuman et al., 2003; Strickler et al., 2005) . A similar correlation was seen between low CD4 count and progression of cervical lesions (Six et al., 1998; Delmas et al., 2000; Schuman et al., 2003) . In the WIHS, a higher incidence of any SIL among WHIV with CD4 counts lower than 500 cells/mm 3 was reported, compared with women with CD4 counts of more than 500 cells/mm 3 . Incidence rates in less-immunocompromised women (CD4 counts > 500 cells/mm 3 ) seemed similar to those in HIVnegative women .
Two studies assessed the association between incidence or progression of SIL and high HIV viral load. Massad et al. (2001) reported an increased incidence and progression of SIL in women with high HIV viral load. Schuman et al. (2003) , however, did not confirm this finding. Massad et al. (2001) also found HIV viral load to be associated independently with a higher progression of SIL, suggesting a possible HPV-HIV viral interaction, where the level of HIV-associated immunosuppression, through low CD4 count, would determine SIL incidence and regression.
Risk factors for SIL in women with HIV infection
Most behavioral risk factors such as number of sexual partners, age at sexual debut, parity, and history of sexually transmitted infections, act as cofactors for SIL development in the presence of HPV infection. Therefore, in multivariate analysis, it is often (persistent) HPV infection that stands out as the sole or most important independent risk factor for SIL Delmas et al., 2000; Hawes et al., 2006) . In studies comparing HIV-positive and HIV-negative women, HIV also remains an independent risk factor for SIL after controlling for HPV infection (Wright et al., 1994; Six et al., 1998; Temmerman et al., 1999; Massad et al., 2001) . A meta-analysis of 15 studies (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) by Mandelblatt et al. (1999) found that although the association between HPV and SIL was the strongest (OR: 5.10; 95% CI: 4.28-6.10), HIV probably played an important role in SIL development (OR: 1.24; 95% CI: 1.04-1.49) by interacting as a definitive cofactor with HPV.
Association between HIV and invasive cervical carcinoma Prevalence and incidence of invasive cervical carcinoma in women with HIV infection A 1996 study by the International Agency for Research on Cancer of the relationship between HIV and cervical cancer concluded that there was no evidence of a significant increase in the incidence of cervical cancer among WHIV (IARC, 1996) . As shown in Table 4 , however, there are now many cancer registry linkage studies that show an increased risk of cervical cancer especially in developed countries where endemic rates of cervical cancer are relatively low and where women have better access to care and longer survival after HIV infection. Frisch et al. (2000) showed a relative risk (RR) of 5.4 for ICC among WHIV in the United States compared with the general population in a record-linkage study in the period 1995-1998 with a total of 51 760 WHIV included. Some of the highest risks are reported by Franceschi et al. (1998) and Dal Maso et al. (2003) , who found evidence of an increased SIR of 21.8 for ICC in WHIV compared with the general population in Italy, and recently Galceran et al. (2007) from Spain, who reported an SIR of 41.8. One study showed that WHIV had more advanced ICC disease than HIV-negative women (OR: 3.1). In the multiple logistic regression analysis, however, only symptom duration and lack of a recent Pap smear were significant risk factors for advanced ICC disease, and thus results were similar for HIV-positive and HIVnegative women (Fruchter et al., 1998) . In Africa, two population-based cancer registries from Uganda (Parkin et al., 1999) and Zimbabwe (Chokunonga et al., 1999) have investigated changes in the incidence of AIDS-related cancer over time, as HIV prevalence has increased in both populations. The registries were examined over the periods 1960 in Uganda and 1990 Zimbabwe. Background population-based HIV prevalence in the adult population rose from 0 to 30% in Uganda and up to 25% by 1997 in Zimbabwe. Both surveys concluded that some AIDS-related cancers did rise over time: Kaposi sarcoma, squamous cell carcinoma of the conjunctiva, and non-Hodgkin's lymphoma; however, this was not seen for ICC. In both countries, there were no temporal changes in the mean age at ICC presentation. Only recently, Mbulaiteye et al. (2006) reported in a record-linkage study from Uganda an increased SIR of 2.4 for cervical cancer. Data from South Africa showed an increased risk of cervical cancer in WHIV (Sitas et al., 2000) , whereas this was not seen in a Kenyan study (Gichangi et al., 2002) . The Kenyan study, however, did report that, on average, age at presentation of ICC was 5 years lower in WHIV compared with HIVnegative women. A similar study from Durban, South Africa, reported a quadrupling of HIV seroprevalence among women with ICC over the period 1990-1999, with a background increase of adult population HIV seroprevalence from 1.6 to 32.5% (Moodley et al., 2001) . The mean age of WHIV with ICC was also 15 years lower than that of HIV-negative women with ICC. A casecontrol study in Nairobi, Kenya, reported a higher HIV prevalence among women with ICC compared with women with uterine fibroids, particularly in the younger age groups (< 35 years; Gichangi et al., 2003) . It is noteworthy that WHIV with ICC included in this study also had relatively high CD4 counts (only 17% had CD4 < 200 cells/mm 3 ).
Thus, we may conclude that the association between HIV and ICC has finally been established for both developed and developing countries. The earlier apparent lack of association might have been because of the lack of antiretroviral therapy, which enables women to survive long enough to develop an invasive carcinoma.
Effect of highly active antiretroviral therapy on human papillomavirus natural history, cervical dysplasia, and cancer
The mortality rate and life expectancy of HIV-infected patients changed significantly owing to the introduction of HAART, which effectively improved their immunological and virological status and effected a consistent reduction of most of the HIV-related opportunistic diseases, including tumors such as Kaposi's sarcoma and non-Hodgkin's lymphoma (International Collaboration on HIV and Cancer, 2000) .
Effect of highly active antiretroviral therapy on human papillomavirus infection
Studies show that cervical HPV infection persists in a high proportion of patients receiving HAART Lillo et al., 2001; Chin-Hong and Palefsky, 2002; Conley et al., 2002; de Sanjosé and Palefsky, 2002) . Although potent anti-HIV regimens have a clear effect on restitution of the patient's immune capacity in terms of increase in CD4 counts, this does not seem sufficient to influence high-risk HPV persistence. Further research, however, is needed on this issue.
Effect of highly active antiretroviral therapy on cervical dysplasia
The effect of antiretroviral therapy on cervical neoplasia is still debated because a clear trend towards a reduction or increase in the prevalence of cervical neoplasia with use of HAARTor other antiretroviral therapy has not been found. One of the earliest studies on this topic described the early regression of cervical lesions in women receiving protease inhibitor therapy after a 5-month follow-up period . More recently, the same group confirmed a higher regression rate of CIN in HAART-treated women (Heard et al., 2002) . The WIHS cohort study showed that WHIV on HAART were 40% more likely to have SIL regression and less likely to have SIL progression . The two latter studies showed HAART to be independently associated with CIN regression. In contrast, Ellerbrock et al. (2000) did not observe differences in CIN incidence between women untreated or treated with different antiretroviral therapy medication (monotherapy or a combination) during an observation period of 30 months.
A longitudinal study with a mean follow-up of 15.4 months reported on SIL outcomes in women untreated or treated with different antiretroviral regimens (Lillo et al., 2001) . HAART-treated patients showed the best recovery in terms of HIV viraemia suppression and CD4 cell count (mean CD4 increase 88 ± 17.9 cells/mm 3 ). The latter was also described by Moore et al. (2002) . No beneficial effect of HAART was, however, found on incident cases of SIL or on the progression/regression rate of lesions after adjusting for CD4 cell count (Lillo et al., 2001) . In a subsequent study (Uberti-Foppa et al., 2003) , the former group demonstrated that, after a median follow-up period of 36.4 months, only clinically stable patients (with or without treatment) showed a reduction in the prevalence or progression of cervical lesions when compared with patients with clinically worsening HIV diseases.
Effect of highly active antiretroviral therapy on ICC
Data concerning the impact of HAART on the incidence of ICC are still incomplete and controversial. One large study compiled cervical cancer data from 23 studies, including 47 936 HIV-positive individuals, conducted in North America, Europe, and Australia from 1992 to 1999 and concluded that there was no significant change in the incidence rate of cervical cancer during this period (pre-HAART and post-HAART; International Collaboration on HIV and Cancer, 2000) . The authors, however, commented that the evaluation was hampered by a small number of incident ICC in the cohorts and that a longer follow-up time was needed.
Conclusion
There is overwhelming evidence of an association between HIV infection and a higher prevalence, incidence and persistence of cervical HPV infection and correlated prevalence, incidence, persistence and progression of cervical SIL. Although it was more difficult to establish, the association between HIV and ICC is now fully recognized, also for developing countries. The progression of HSIL to ICC seems less dependent on immunosuppression, in contrast to the development of SIL (Dal Maso et al., 2001; Palefsky and Holly, 2003) . HAART also seems to have little, if any, beneficial effect on the evolution of SIL. HAART does, however, prolong the life expectancy of WHIV, hence increasing the opportunity for persistent high-risk HPV infection to cause ICC over time (Dal Maso et al., 2001; Schuman et al., 2003; Heard et al., 2004; Strickler et al., 2005; Mbulaiteye et al., 2006) . Prevention of ICC by cervical screening will therefore be critical in WHIV using HAART (Franceschi and Jaffe, 2007) . To evaluate the effect of maturation of the HIV epidemic on incidence of ICC, cohorts of WHIV on HAART should be monitored closely, particularly in regions of the world where cervical screening is not readily available.
